Key facts
- This page summarizes Ted White's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 23 Jul 2024, 18:13.
Ted White - 22 Jul 2024 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)
- Issuer symbol
- VRCA
- Report date
- 22 Jul 2024
- Net transaction value
- -$230,306
- Form type
- 4
- Accepted by SEC
- 23 Jul 2024, 18:13:03 UTC
- Previous filing
- 19 Mar 2024
- Next filing
- 28 Aug 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
SEC evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Ted White filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 23 Jul 2024.
Change
- Previous filing in this sequence was filed on 19 Mar 2024.
- Current net transaction value: -$230,306.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRCA
transaction
Common Stock
Sale
- Transaction value
- $229,231
- Shares
- -32,469
- Change %
- -11%
- Price
- $7.06
- Shares after
- 250,121
- Date
- 22 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
VRCA
transaction
Common Stock
Sale
- Transaction value
- $1,075
- Shares
- -154
- Change %
- -0.06%
- Price
- $6.98
- Shares after
- 249,967
- Date
- 23 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.